Stockscreener 앱 받기
107.42
1.10%
-1.19
시간 외 거래:
106.92
-0.50
-0.47%
전일 마감가:
$108.61
열려 있는:
$108.27
하루 거래량:
21.77M
Relative Volume:
3.13
시가총액:
$186.79B
수익:
$44.33B
순이익/손실:
$6.48B
주가수익비율:
29.01
EPS:
3.7033
순현금흐름:
$6.92B
1주 성능:
-11.78%
1개월 성능:
-13.75%
6개월 성능:
-14.63%
1년 성능:
-12.82%
1일 변동 폭
$106.08
$110.05
1주일 범위
$105.78
$122.49
52주 변동 폭
$105.78
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
107.42 | 188.86B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
92.51 | 135.38B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.04 | 137.16B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.88 | 129.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.66 | 49.00B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Assessing Abbott Laboratories (ABT) Valuation After Q4 2025 Earnings Miss And Softer 2026 Guidance - Yahoo Finance New Zealand
Citigroup Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00 - MarketBeat
Abbott India Under Scrutiny Due To Cough Syrup Supply ChainAbbott Laboratories (NYSE:ABT) - Benzinga
Tesla To $360? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Sanford C. Bernstein Lowers Abbott Laboratories (NYSE:ABT) Price Target to $125.00 - MarketBeat
UBS reiterates Buy rating on Abbott Labs stock with $158 price target - Investing.com
Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2 - Benzinga
Abbott Faces Near-Term Headwinds in Nutrition and Slower Long-Term Libre Growth - Morningstar
Abbott Laboratories (NYSE:ABT) Given New $130.00 Price Target at Raymond James Financial - MarketBeat
Abbott Laboratories (NYSE:ABT) Price Target Cut to $132.00 by Analysts at Oppenheimer - MarketBeat
The Goldman Sachs Group Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott Laboratories (NYSE:ABT) Price Target Lowered to $135.00 at Royal Bank Of Canada - MarketBeat
Oppenheimer Adjusts Price Target for Abbott Laboratories (ABT) | - GuruFocus
2 Healthcare Names That Could Get a Big Boost From Earnings - Investing.com
Abbott Labs stock price target lowered to $125 by Bernstein SocGen - Investing.com
Evercore ISI Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Is The Fall In Abbott Stock Justified? - Forbes
Piper Sandler Lowers Price Target for Abbott Laboratories (ABT) - GuruFocus
Abbott Labs stock price target lowered to $135 by RBC Capital By Investing.com - Investing.com Nigeria
TD Cowen lowers Abbott Labs stock price target on Q4 revenue miss - Investing.com
Piper Sandler lowers Abbott Labs stock price target on nutrition segment weakness By Investing.com - Investing.com South Africa
Teacher Retirement System of Texas Sells 122,066 Shares of Abbott Laboratories $ABT - MarketBeat
How Did Abbott Fare In Q4 And What Lies Ahead? - Trefis
Piper Sandler Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Benchmark reiterates Buy rating on Abbott Labs stock amid tepid Q4 - Investing.com
Abbott Labs stock price target lowered to $135 by RBC Capital - Investing.com
Abbott faces India scrutiny in cough syrup abuse investigation, documents show - Reuters
Abbott Laboratories (NYSE:ABT) Q4 2025 earnings call transcript - MSN
Piper Sandler lowers Abbott Labs stock price target on nutrition segment weakness - Investing.com
Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript - Insider Monkey
Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings - Fierce Biotech
Abbott Labs stock price target lowered to $122 by Wells Fargo on nutrition headwinds - Investing.com
Abbott Laboratories: Buy This Dividend King On Sale Now (NYSE:ABT) - Seeking Alpha
Abbott Labs stock price target lowered to $132 at Oppenheimer on Q4 results - Investing.com Australia
Abbott Labs stock price target lowered to $145 by Jefferies on nutrition segment miss - Investing.com Nigeria
Strs Ohio Sells 35,951 Shares of Abbott Laboratories $ABT - MarketBeat
Simplicity Wealth LLC Has $2.22 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Labs stock price target lowered to $130 by Raymond James - Investing.com
Abbott stock sank 10% on earnings — what traders watch before the bell - TechStock²
Abbott Labs (ABT) Stock Tumbles 8% as Weak Nutrition Sales Offset Strong Device Growth - CoinCentral
Abbott Stock Suffers Worst Drop In More Than 20 Years - Eudaimonia and Co
Abbott Laboratories Share Price Falls 8% After Revenue Miss | Stock Market Today - Samco
ABT Q4 Deep Dive: Nutrition Weakness and Innovation Shape 2026 Outlook - FinancialContent
Abbott Stock Suffers Worst Drop in More Than 20 Years - The Wall Street Journal
Abbott has mixed Q4 results, but medtech sales up 12.3% - MassDevice
Abbott Laboratories Earnings Call: Devices Offset Nutrition Drag - TipRanks
Traders Purchase High Volume of Put Options on Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott misses Q4 expectations - BioWorld MedTech
Stock Movers: Carvana, Abbott, Intel - Bloomberg
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness - The Chronicle-Journal
Intel, GE Aerospace, Moderna, Abbott, Mobileye, McCormick, and More Stock Movers - Barron's
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.34%
1.01%
자본화:
|
볼륨(24시간):